Esophageal cancer
Drug research and approvals for esophageal cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 547 studies of esophageal cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 12 drug trials for it since 2013, and FDA has 10 approved and 22 open orphan designations naming it.
- Recruiting worldwide: 547
- Trials authorized in Canada: 12
- FDA orphan approvals: 10
- EU medicines: 0
- Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or…NCT07920224 · Phase 2 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · starts Jul 19, 2025
- The Effectiveness of Structured Swallowing Exercise Therapy in Patients With Nasopharyngeal Carcinoma: An Assessment of…NCT07909538 · Not applicable · Ira Mistivani, dr. Sp.KFR.N.M.(K). · starts Sep 9, 2026
- CR-002 in Adult Participants With Locally Advanced or Metastatic Solid TumorsNCT07909031 · Phase 1 / Phase 2 · Crescent Biopharma, Inc. · starts Oct 21, 2026
- A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.NCT07903415 · Phase 1 · Pfizer · starts Nov 5, 2026
- SPADE Clinical Trial.NCT07892183 · Not applicable · National Cancer Center, Korea · starts Jun 25, 2025
- A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid TumorsNCT07887971 · Phase 1 · Aktis Oncology, Inc. · starts Nov 1, 2026
- Modular Robot-Assisted Versus Conventional Minimally Invasive Esophagectomy for Esophageal CancerNCT07888140 · Phase 3 · Ruijin Hospital · starts Oct 15, 2026
- Biomarker Investigation for Early Gastric Cancer DetectionNCT07884669 · Not applicable · Centre Leon Berard · starts Nov 12, 2026
- A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in…NCT07863141 · Phase 2 · Sun Yat-sen University · starts Oct 12, 2026
Approved 1
- TislelizumabProgrammed cell death protein 1 inhibitor
Phase 3 12 of 44
- CisplatinDNA inhibitor
- PaclitaxelTubulin inhibitor
- FluorouracilThymidylate synthase inhibitor
- CarboplatinDNA inhibitor
- OxaliplatinDNA inhibitor
- DocetaxelTubulin inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- SintilimabProgrammed cell death protein 1 antagonist
- CetuximabEpidermal growth factor receptor erbB1 inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
- CapecitabineThymidylate synthase inhibitor
- CamrelizumabProgrammed cell death protein 1 antagonist
Phase 2 12 of 73
- GefitinibEpidermal growth factor receptor erbB1 inhibitor
- CadonilimabProgrammed cell death protein 1 inhibitor
- AfatinibEpidermal growth factor receptor erbB1 inhibitor
- CatequentinibVascular endothelial growth factor receptor 2 inhibitor
- CelecoxibCyclooxygenase-2 inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- PanitumumabEpidermal growth factor receptor erbB1 inhibitor
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- Hpph
- HydroxyureaRibonucleoside-diphosphate reductase RR1 inhibitor
- SunitinibMacrophage colony stimulating factor receptor inhibitor
- PemetrexedThymidylate synthase inhibitor
Phase 1 or earlier 12 of 42
- LMB-9Lewis Y antigen binding agent
- AcetaminophenCyclooxygenase inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- SonidegibSmoothened homolog inhibitor
- TopotecanDNA topoisomerase I inhibitor
- VandetanibTyrosine-protein kinase SRC inhibitor
- TerfenadineHistamine H1 receptor antagonist
- UmbralisibPI3-kinase p110-delta subunit inhibitor
- VorinostatHistone deacetylase 1 inhibitor
- SorafenibSerine/threonine-protein kinase RAF inhibitor
- LinagliptinDipeptidyl peptidase IV inhibitor
- AzacitidineDNA (cytosine-5)-methyltransferase 3A inhibitor
How its trials ended
1,412 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 277 whose ending is known, 30% met their primary endpoint, 10% missed it and 60% stopped early.
- Ongoing42430%
- Completed, result not reported42030%
- Status unknown29121%
- Met its primary endpoint846%
- Stopped: other or unclear765%
- Stopped: enrollment or feasibility514%
- Missed its primary endpoint272%
- Stopped: sponsor or business decision191%
- Stopped: lack of efficacy101%
- Stopped: funding6<1%
- Stopped: safety4<1%
| Dec 18, 2025 | Rosetta gastric-204: a blinded, randomized, phase 2/3 study of pumitamig in combination with chemotherapy versus nivolumab in combination with chemotherapy in…Pumitamig (BMS-986545; BNT327) / Opdivo [nivolumab (BMS-936558)] / Calcium… | Bristol-Myers Squibb | Ongoing |
| Sep 19, 2025 | A phase III, multicentre, randomised controlled study of sonesitatug vedotin in combination with fluoropyrimidine with or without rilvegostomig in first-line…Sonesitatug vedotin (AZD0901) / Rilvegostomig (AZD2936) | AstraZeneca Pharmaceuticals | Ongoing |
| Oct 25, 2024 | A phase 2 randomized study to evaluate the safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, leucovorin, and budigalimab as…Telisotuzumab adizutecan (ABBV-400) / Budigalimab (ABBV-181) / Fluorouracil /… | AbbVie | Ongoing |
| Oct 20, 2022 | A randomized, open-label, multicenter phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in participants with…Zimberelimab (AB122) / Domvanalimab (AB154) / Oxaliplatin / Leucovorin /… | Arcus Biosciences | Closed |
| May 19, 2022 | A phase I study of organ-preserving endoscopic resection & adjuvant radioimmuno-chemotherapy for esophageal cancer (opera radio)Imfinzi | University of Manitoba | Ongoing |
| Nov 16, 2021 | Pioneering pre- and post-operative integrative care to improve thoracic cancer quality of care: the thoracic peri-operative integrative surgical care…Vitamin D | Ottawa Hospital Research Institute | Ongoing |
| Oct 8, 2021 | A phase 3, randomized study to evaluate the efficacy and safety of pembrolizumab (MK-3475) + lenvatinib (E7080/MK-7902) + chemotherapy compared with standard…MK-7902 (E7080/lenvatinib) / MK-3475 (pembrolizumab) | Merck & Co. (MSD) | Closed |
| Aug 12, 2021 | A randomized trial comparing early local chemoradiation therapy +/- surgery versus systemic therapy for patients with esophageal or gastric cancer with…Fluorouracil | Research Institute of The McGill University Health Centre | Ongoing |
| Feb 11, 2020 | A randomized, double-blind, placebo-controlled phase 3 trial of pembrolizumab (MK-3475) versus placebo in participants with esophageal carcinoma receiving…Keytruda (pembrolizumab) | Merck & Co. (MSD) | Closed |
| May 26, 2017 | A randomized, double-blind, placebo-controlled phase III clinical trial of pembrolizumab (MK-3475) in combination with cisplatin and 5-fluorouracil versus…Keytruda / Cisplatin / Fluorouracil | Merck & Co. (MSD) | Ongoing |
| Aug 25, 2026 | Ziihera(1) in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr, for the first-line treatment of adult… | Jazz Pharmaceuticals Ireland Limited | Approved |
| Aug 25, 2026 | TevimbraIn combination with zanidatamab-hrii and fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment for adults… | BeOne Medicines USA, Inc. | Approved |
| Mar 3, 2025 | TevimbraIn combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal… | BeOne Medicines USA, Inc. | Approved |
| Mar 13, 2024 | TevimbraAs a single agent, for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior… | BeOne Medicines USA, Inc. | Approved |
| May 27, 2022 | OpdivoIn combination with ipilimumab, for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous… | Bristol-Myers Squibb Company | Approved |
| May 27, 2022 | OpdivoIn combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with… | Bristol-Myers Squibb Company | Approved |
| May 20, 2021 | OpdivoAdjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who… | Bristol-Myers Squibb Company | Approved |
| Apr 16, 2021 | OpdivoIn combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with advanced or metastatic… | Bristol-Myers Squibb Company | Approved |
| Jun 10, 2020 | OpdivoOpdivo (nivolumab) indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell… | Bristol-Myers Squibb Company | Approved |
| Dec 27, 1995 | PhotofrinPhotodynamic therapy with PHOTOFRIN for the palliation of patients with completely obstructing esophageal cancer, or of patients with… | QLT Phototherapeutics, Inc. | Approved |
| Aug 30, 2026 | Sonesitatug vedotinTreatment of esophageal cancer | AstraZeneca Pharmaceuticals LP | Designated |
| Jan 15, 2026 | Ifinatamab deruxtecanTreatment of esophageal cancer | Daiichi Sankyo, Inc. | Designated |
| May 22, 2025 | Fibroblast activation protein inhibitor radiolabeled with…Diagnostic for the management of esophageal cancer | SOFIE Co. dba SOFIE | Designated |
| Apr 25, 2025 | Nectin-4-targeting polypeptide conjugated to MMAETreatment of esophageal cancer | ConjuStar (Zhuhai) Biologics Co., Ltd. | Designated |
| Nov 14, 2024 | LenvatinibTreatment of esophageal cancer | Eisai Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA